Medicines Development for Global Health
Fast Company magazine has named MDGH Founder Mark Sullivan to its 2019 list of ‘100 Most Creative People in Business’
The award is for his vision in establishing Medicines Development for Global Health to address health inequity, and the novel funding approach that was applied....
The Global Health Investment Fund and Medicines Development for Global Health Announce the Sale of Priority Review Voucher
The sale of the Tropical Disease Priority Review Voucher follows the FDA’s approval of moxidectin, an oral treatment for river blindness....
MDGH has been named as one of Fast Company’s ‘World’s Most Innovative Companies’ for 2019, ranked 7th most innovative not-for-profit company.
Fast Company is a highly-regarded magazine based in New York. It is dedicated to the intersection of business, innovation, and design, and engages with the world’s most influential leaders and companies on the future of business...
MDGH AWARDED 2018 AUSBIOTECH AND J&J INNOVATION INDUSTRY EXCELLENCE AWARD
Medicines Development for Global Health (MDGH) is delighted to announce that it has received the 2018 AusBiotech and Johnson & Johnson Innovation Industry Excellence Award in the “Established Company of the Year Award” category.
MDGH FOUNDER NAMED 2019 VICTORIAN AUSTRALIAN OF THE YEAR
Medicines Development for Global Health Founder and Managing Director Mark Sullivan was named 2019 Victorian Australian of the Year this week for his vision for bringing urgently needed medicines into the fight against Neglected Tropical Diseases.
COVERS MOXIDECTIN APPROVAL
Mark Sullivan, the founder, Managing Director and Board Member of Medicines Development for Global Health, was interviewed by Dr. Norman Swan on today’s
, broadcast nationally in Australia. The interview covers MDGH’s business model, the FDA’s approval of Moxidectin, and the medicine’s potential to help the fight against river blindness, which is a leading global cause of preventable blindness. Click anywhere to listen to a recording on the ABC’s website.
U.S. FDA APPROVES MOXIDECTIN FOR THE TREATMENT OF RIVER BLINDNESS
Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The FDA has also awarded MDGH a priority review voucher ....
Human Neonatal Rotavirus Vaccine Paper in NEJM
The Rotavirus Vaccine Program at the Murdoch Children’s Research Institute has published results from their study evaluating the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing rotavirus gastroenteritis. Amanda Handley, Director at Medicines Development, has been providing project management services on this program since January 2013. Congratulations to all the program team...
Moxidectin Phase III Study Lancet Publication
Medicines Development for Global Health is delighted to announce the publication of the moxidectin Phase III study in the Lancet. The paper’s authors, coordinated by the previous Sponsor of moxidectin, the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, concluded that “Moxidectin would therefore be expected to reduce parasite transmission between treatment...
Good Management Practice: Partners Address Project Management Challenges for Neglected Tropical Disease Study
The February 2018 edition of Clinical Researcher’s Q&A with Mark Sullivan and Craig Rayner on good management practice. Please click here to read the Q&A.